Reckitt Sees Positive Signs For Cold & Flu Brands After Difficult First Half
Executive Summary
Reckitt is seeing good signs in the US that cold and flu incidence is returning to more normal levels. However, the upswing came too late to materially impact first-half sales at its Health business, which posted turnover down 14%.
You may also be interested in...
Reckitt Capitalizes As COVID Moves From Pandemic To Endemic
Reckitt's OTC sales jumped 60% in the first half of 2022 as the milder omicron COVID-19 variant drove up demand for its leading cold and flu brands. This strong showing has led the firm to raise its full-year group sales guidance from 1-4% to 5-8%.
Euro Q3 Consumer Health Earnings Preview: GSK, Sanofi, Bayer And Reckitt
Major Europe-based consumer health players GSK, Sanofi, Bayer and Reckitt continue to deal with the fallout of the COVID-19 pandemic while implementing long-term strategies to drive growth. This earnings preview highlights what to look out for as these four firms report their third-quarter results over the coming weeks.
Reckitt Offloads Troubled Chinese Infant Nutrition Business
Reckitt is to divest its Chinese infant formula business in a deal worth $2.2bn following a strategic review of the troubled unit.